ADS-ADEA 2015* Jessica Chang
Private Practice, VIC, Australia
Presentations this author is a contributor to:
The glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, inhibits small intestinal motility, flow, transit and absorption of glucose in health and type 2 diabetes: a randomised controlled trial. (#71)
4:15 PM
Chinmay S Marathe
ADS Clinical Orals: Gut and Glycaemia
Effects of exenatide on the blood pressure and heart rate responses to intraduodenal glucose in type 2 diabetes (#168)
4:30 PM
Chinmay S Marathe
ADS Clinical Orals: Therapies for Type 2 Diabetes